QNZ (EVP4593)

Catalog No.S4902

For research use only.

QNZ (EVP4593) shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM in Jurkat T cells, respectively.

QNZ (EVP4593) Chemical Structure

CAS No. 545380-34-5

Selleck's QNZ (EVP4593) has been cited by 106 publications

Purity & Quality Control

Choose Selective NF-κB Inhibitors

Other NF-κB Products

Biological Activity

Description QNZ (EVP4593) shows potent inhibitory activity toward both NF-κB activation and TNF-α production with IC50 of 11 nM and 7 nM in Jurkat T cells, respectively.
Targets
TNF-α [1]
(Jurkat T cells)
NF-κB [1]
(Jurkat T cells)
7 nM 11 nM
In vitro

EVP4593 inhibits TNF-a production from murine splenocytes stimulated with LPS with IC50 of 7 nM. [1] EVP4593 (300 nM) entails a significant decrease of amplitude of store-operated currents (approximately by 60%), induced by application of 1 μM thapsigargin in Htt138Q cells, thus prevents abnormal store-operated calcium entry. EVP4593 is able to inhibit the activity of channels containing TRPC1 as one of the subunits, but has no effect on homooligomer channels composed exclusively of TRPC1. [2] QNZ (40 nM) completely abolishes the enhancement of neurite number and length evoked by laminin treatment of the schwann cells. QNZ reduces the neurite length by 61.36% of the schwann cells. QNZ significantly inhibits laminin-induced neurite outgrowth. QNZ also greatly diminishes the neurite elongation after 72 hours culture implying that both initial sprouting and longer term growth and extension seen in response to schwann cells seeded on laminin is mediated by NF-κB. [3] QNZ (10 nM) abolishes LPS-induced up-regulation of CSE expression in rat neutrophil. [4] QNZ (100 nM) blocks the induction effects of GRO/KC on K currents in IB4-negative neurons. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat NGW4SnNMcW6jc3WgZZN{[Xl? M13XTJ4yOCEQvF2= NYGwfI83[2G3c3XzJG5HNc78QjDJcohq[mm2aX;uJJdqfGhiRVO1NEBw\iB7IH7N NYLRd|ZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NFAzOTNpPkKxO|AxOjF|PD;hQi=>
Jurkat NUTCUIhUTnWwY4Tpc44h[XO|YYm= MlHJN{DPxE1? MlPQZ4F2e2W|IGPPR{BKdmirYnn0bY9v NXPle413RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NFAzOTNpPkKxO|AxOjF|PD;hQi=>
neurons NVuzd5hETnWwY4Tpc44h[XO|YYm= NVzTXZZTOzByIH7N MnSybY5pcWKrdDDzeI9z\S2xcHXyZZRm\CCFYUKrJIVvfHK7 NGi0UXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUewNFIyOyd-MkG3NFAzOTN:L3G+
SK-N-SH Mn3iSpVv[3Srb36gZZN{[Xl? MXezNFAhdk1? NYTRSm1ucW6qaXLpeJMhXFKSQ{GtV5VxeG:{dHXkJHNQSyCFYUKrJIN2enKnboTz NYHlOGJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NFAzOTNpPkKxO|AxOjF|PD;hQi=>
neurons NXTBSW1JTnWwY4Tpc44h[XO|YYm= MoOxN|AxKG6P NWH0e2VWeHKxdHXjeEB[SUNzMkigUXNPKG[{b32g[4x2fGGvYYTlJJRwgGmlaYT5 MknuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MECyNVMoRjJzN{CwNlE{RC:jPh?=
GABA MS-like neurons NWLMRo01TnWwY4Tpc44h[XO|YYm= M2[4dFExOCCwTR?= NXjucHNWemW|Y4Xld{Bi[m6xcn3hcEBUV0NvbXXkbYF1\WRiY3HsZ4l2dSCnboTyfS=> NFTHNJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4NFEzQSd-MkewPFAyOjl:L3G+
GABA MS-like neurons NY\OW29nTnWwY4Tpc44h[XO|YYm= M1[2XVExODBibl2= Mknpco9zdWGuaYrld{B1cGViboXtZoVzKG:oIHz5d49{d22ncz;heZRweGijZ3;zc41mew>? MmXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOECxNlkoRjJ5MEiwNVI6RC:jPh?=
GABA MS-like neurons NXTnWHp7TnWwY4Tpc44h[XO|YYm= MX6xNFAhdk1? NHHMZWJz\XOldXXzJIFocW6pIH7leZJwdnNiZoLvcUBk\WyuIHTlZZRp NUjIe|BLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFAyOjlpPkK3NFgxOTJ7PD;hQi=>
HepG2 NXP1[pp5TnWwY4Tpc44h[XO|YYm= M{jjc2hCWl[DUlS6JGlvcGmkaYTpc44hd2ZibHn2[ZIhe3SjZ3WgVIxie22xZHn1cUBj\XKpaHXpJIlv\mWldHnvckBqdiCKZYDHNkBk\WyuczygTWM2OCB;IECuNFEzKM7:TT6= MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OE[xNlQoRjJ{NUi2NVI1RC:jPh?=
HepG2 M4DOOWZ2dmO2aX;uJIF{e2G7 MYGwMlEhfG9iMUCgeW0> MkHzNUBpeg>? MlrNTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2rbnT1Z4VlKE6Ia3HwdIFDKCi3bnvuc5dvKG:{aXfpckku\GWyZX7k[Y51KHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBmgHC{ZYPz[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNE4yKHSxIEGwJJVOKGmwY4XiZZRm\CCob4KgNUBpeiCycnnvdkB1dyCWTl\hcJBp[SCrbnT1Z5Rqd25ibXXhd5Vz\WRiYX\0[ZIhPiCqcoOgZpkh\HWjbD3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzOUi1OEc,OjN{MUm4OVQ9N2F-
Assay
Methods Test Index PMID
Western blot NF-κB p65 / OPN / Tissue factor / Thrombin ; VEGF / TNF-α / IL-1β / IL-6 / MMP-2 / MMP-9 / NF-κB p65(Ser536) 29061995 28693192
Growth inhibition assay Cell viability 28693192
In vivo EVP4593 (1 mg/kg, i.p.) dose-dependently inhibits carrageenin-induced paw edema in rats. [1]

Protocol (from reference)

Animal Research:[1]
  • Animal Models: male SD rats with carrageenin induced paw edema
  • Dosages: 1 mg/kg
  • Administration: intraperitoneal injection

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% hydroxyethyl cellulose
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 356.42
Formula

C22H20N4O

CAS No. 545380-34-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C(C=C1)OC2=CC=C(C=C2)CCNC3=NC=NC4=C3C=C(C=C4)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy QNZ|QNZ ic50|QNZ price|QNZ cost|QNZ solubility dmso|QNZ purchase|QNZ manufacturer|QNZ research buy|QNZ order|QNZ mouse|QNZ chemical structure|QNZ mw|QNZ molecular weight|QNZ datasheet|QNZ supplier|QNZ in vitro|QNZ cell line|QNZ concentration|QNZ nmr|QNZ in vivo|QNZ clinical trial|QNZ inhibitor|QNZ NF-κB inhibitor